Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Ratios

C4 Therapeutics (CCCC) Beginning Cash Balance (2023)

C4 Therapeutics has reported Beginning Cash Balance over the past 1 years, most recently at $11.0 million for Q3 2023.

For Q3 2023, Beginning Cash Balance changed N/A year-over-year to $11.0 million; the TTM value through Jun 2024 reached $11.0 million, up 633.33%, while the annual FY2023 figure was $12.5 million, N/A changed from the prior year.
Beginning Cash Balance for Q3 2023 was $11.0 million at C4 Therapeutics, up from $750000.0 in the prior quarter.
Over five years, Beginning Cash Balance peaked at $11.0 million in Q3 2023 and troughed at $750000.0 in Q1 2023.